US Health Secretary RFK Jr Expands Access to Unapproved Peptides
US Health Secretary Robert F. Kennedy Jr. has unilaterally granted access to six unproven peptide drugs by placing them under an enforcement discretion policy. Health experts and FDA scientists have raised concerns regarding the decision due to a lack of human clinical trials and unknown long-term effects.
US Health Secretary RFK Jr. has unilaterally granted access to six unproven peptide drugs that are popular with MAHA, placing these substances under an enforcement discretion policy and overruling the FDA. Some reports say that FDA scientists fiercely opposed the Trump administration's move to ease access to these peptide drugs.
Health experts have cautioned against using these medications, citing a total lack of clinical trials for humans and unknown long-term effects. The effort to loosen the rules on these unproven treatments faced strong pushback from agency scientists within the FDA.
Peptide peddlers are reportedly cheering the decision following the unilateral action by the US Health Secretary. The policy change marks a significant shift in regulatory approach despite the warnings and opposition from scientific and medical professionals.
Turkrazzi roundup · from 3 sources
